Ardelyx Company Profile (NASDAQ:ARDX)

About Ardelyx

Ardelyx logoArdelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ARDX
  • CUSIP:
Key Metrics:
  • Previous Close: $11.83
  • 50 Day Moving Average: $10.58
  • 200 Day Moving Average: $9.00
  • 52-Week Range: $47,250,000.00 - $6.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.47
  • P/E Growth: -0.13
  • Market Cap: $581.65M
  • Outstanding Shares: 47,250,000
  • Beta: 0.09
  • Return on Equity: -64.32%
  • Return on Assets: -59.04%
  • Current Ratio: 10.70%
  • Quick Ratio: 10.70%
Additional Links:
Companies Related to Ardelyx:

Analyst Ratings

Consensus Ratings for Ardelyx (NASDAQ:ARDX) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.13 (71.61% upside)

Analysts' Ratings History for Ardelyx (NASDAQ:ARDX)
DateFirmActionRatingPrice TargetDetails
8/10/2016Citigroup Inc.Lower Price TargetBuy$14.00 -> $13.00View Rating Details
6/23/2016WedbushReiterated RatingOutperform$24.00View Rating Details
6/22/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
6/23/2016Leerink SwannReiterated RatingBuyView Rating Details
3/31/2016Ladenburg ThalmannInitiated CoverageBuy$21.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$26.00 -> $21.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$26.00 -> $21.00View Rating Details
12/18/2015BTIG ResearchInitiated CoverageBuy$33.00View Rating Details
(Data available from 9/26/2014 forward)


Earnings History for Ardelyx (NASDAQ:ARDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.02)($0.19)ViewN/AView Earnings Details
2/25/2015($0.06)($0.21)ViewListenView Earnings Details
8/7/2014$1.83$0.44ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ardelyx (NASDAQ:ARDX)
Current Year EPS Consensus Estimate: $-2.72 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.74)($0.73)($0.74)
Q2 20162($0.67)($0.66)($0.67)
Q3 20162($0.78)($0.62)($0.70)
Q4 20162($0.71)($0.63)($0.67)
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.71)($0.71)($0.71)
Q3 20171($0.77)($0.77)($0.77)
Q4 20171($0.72)($0.72)($0.72)
(Data provided by Zacks Investment Research)


Dividend History for Ardelyx (NASDAQ:ARDX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ardelyx (NASDAQ:ARDX)
Insider Ownership Percentage: 15.46%
Institutional Ownership Percentage: 62.84%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.00View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.00View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.00View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.40View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.00View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.65View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.86View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ardelyx (NASDAQ:ARDX)
News IconConsensus Analyst Thoughts for: Ardelyx, Inc. (NASDAQ:ARDX) , Howard Hughes Corporation (NYSE:HHC) - Wall Street Times (press release) (NASDAQ:ARDX) - September 23 at 8:24 AM logoTrending Stocks: TerraForm Power, Inc. (NASDAQ:TERP), Ardelyx, Inc. (NASDAQ:ARDX), American International ... - KC Register (NASDAQ:ARDX) - September 22 at 3:31 PM logoArdelyx to Present at Ladenburg Thalmann 2016 Healthcare Conference (NASDAQ:ARDX) - September 22 at 3:31 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Ardelyx, Inc ... - Frisco Fastball (NASDAQ:ARDX) - September 20 at 3:33 PM
News IconSell-side is Weighing in on Ardelyx, Inc. (NASDAQ:ARDX) Earnings & Targets - Frisco Fastball (NASDAQ:ARDX) - September 19 at 8:22 AM
News IconWhat is the Sell-side Saying About Ardelyx, Inc. (NASDAQ:ARDX)? - Frisco Fastball (NASDAQ:ARDX) - September 18 at 3:32 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Ardelyx, Inc. (NASDAQ:ARDX) - Frisco Fastball (NASDAQ:ARDX) - September 17 at 3:33 PM logoArdelyx, Inc. :ARDX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:ARDX) - September 13 at 3:34 PM
News IconStock in Review: Taking a Closer Look at Ardelyx, Inc. (NASDAQ:ARDX) Shares - Post News (NASDAQ:ARDX) - September 2 at 8:12 AM
News IconShares Moving Higher in Trade: Ardelyx, Inc. (NASDAQ:ARDX) - Post News (NASDAQ:ARDX) - August 25 at 3:35 PM logoAfter Medivation, These 6 Biotech Stocks Could Be M&A Targets Next (NASDAQ:ARDX) - August 22 at 3:37 PM
News IconAnalysts & Crowd Weigh in on Ardelyx, Inc. (NASDAQ:ARDX) Stock ... - Post News (NASDAQ:ARDX) - August 21 at 8:19 AM logoQ2 2016 Aurora Diagnostics Inc Earnings Release - 09:30 am ET (NASDAQ:ARDX) - August 18 at 11:58 AM logoArdelyx to Present at Wedbush PacGrow Healthcare Conference (NASDAQ:ARDX) - August 15 at 10:48 AM logoArdelyx : reports 2Q loss (NASDAQ:ARDX) - August 10 at 3:54 PM logoEdited Transcript of ARDX earnings conference call or presentation 8-Aug-16 8:30pm GMT (NASDAQ:ARDX) - August 9 at 4:39 PM logoArdelyx reports 2Q loss (NASDAQ:ARDX) - August 8 at 9:01 PM logoQ2 2016 Ardelyx Inc Earnings Release - After Market Close (NASDAQ:ARDX) - August 8 at 8:21 AM logoArdelyx to Report Second Quarter 2016 Financial Results on August 8th, 2016 (NASDAQ:ARDX) - August 1 at 3:33 PM logoArdelyx Receives Notice of Allowance of Composition of Matter Patent Covering its Novel Potassium Binder RDX227675 (NASDAQ:ARDX) - August 1 at 8:21 AM logoWedbush Has 3 Stocks to Buy With 70% to 140% Upside Potential (NASDAQ:ARDX) - July 30 at 9:40 AM logoArdelyx (ARDX): RA Capital Management Boosts Stake to 7.7% (NASDAQ:ARDX) - July 29 at 10:44 AM logoInvestors Scour Big Pharma M&A Scene for Next Big Takeover (NASDAQ:ARDX) - July 21 at 2:58 PM logoARDELYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, (NASDAQ:ARDX) - July 20 at 6:07 AM logoKILL Robbins Arroyo LLP: Acquisition of Ardelyx, Inc. (ARDX) by Multiple Acquirers (Private) May Not Be in Shareholders' Best Interests (NASDAQ:ARDX) - July 16 at 11:16 AM logoRobbins Arroyo LLP: Acquisition of Ardelyx, Inc. (ARDX) by Multiple Acquirers (Private) May Not Be in Shareholders' Best Interests (NASDAQ:ARDX) - July 15 at 3:13 PM logoArdelyx to Raise $110 Million in a Private Placement (NASDAQ:ARDX) - July 15 at 8:28 AM logoARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:ARDX) - July 15 at 8:09 AM logoArdelyx (ARDX) Shares March Higher, Can It Continue? (NASDAQ:ARDX) - July 12 at 6:51 AM logoArdelyx (ARDX) Updates on RDX227675, Tenapanor Progress (NASDAQ:ARDX) - June 23 at 11:21 AM logoArdelyx Reports Positive Results From End-of-Phase 2 Meeting With FDA (NASDAQ:ARDX) - June 22 at 8:21 AM logoArdelyx Reports Progress of Development Programs (NASDAQ:ARDX) - June 22 at 7:19 AM logo7:03 am Ardelyx updates on two of its ongoing development programs, discloses positive results from End-of-Phase 2 meeting with the FDA (NASDAQ:ARDX) - June 22 at 7:03 AM logoArdelyx Appoints Robert Bazemore to Its Board of Directors (NASDAQ:ARDX) - June 7 at 9:18 AM logoARDELYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:ARDX) - June 3 at 5:14 PM logoArdelyx to Present at 2016 BIO International Convention (NASDAQ:ARDX) - June 3 at 9:25 AM logoARDELYX, INC. Financials (NASDAQ:ARDX) - May 17 at 1:04 PM logoEdited Transcript of ARDX earnings conference call or presentation 9-May-16 8:30pm GMT (NASDAQ:ARDX) - May 10 at 10:22 AM logoARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ARDX) - May 9 at 5:18 PM logoARDELYX, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ARDX) - May 9 at 5:03 PM logoArdelyx Inc Earnings Call scheduled for 4:30 pm ET today (NASDAQ:ARDX) - May 9 at 4:30 PM logoArdelyx reports 1Q loss (NASDAQ:ARDX) - May 9 at 4:13 PM logoArdelyx to Report Fourth Quarter and Full Year 2015 Financial Results on March 4th, 2016 (NASDAQ:ARDX) - February 25 at 7:00 AM logoArdelyx to Present at the 2016 Leerink Partners Global Healthcare Conference (NASDAQ:ARDX) - February 2 at 4:15 PM logoArdelyx Becomes Oversold (ARDX) (NASDAQ:ARDX) - February 2 at 2:06 PM logoArdelyx Gears Up for Secondary Offering (NASDAQ:ARDX) - January 8 at 11:25 AM logoArdelyx Announces Pricing of Public Offering of Common Stock (NASDAQ:ARDX) - January 7 at 9:23 PM logoArdelyx Announces Proposed Public Offering of Common Stock (NASDAQ:ARDX) - January 6 at 4:57 PM logoARDELYX, INC. Files SEC form 8-K, Other Events (NASDAQ:ARDX) - January 6 at 4:47 PM logoArdelyx Reports Positive Clinical Results of RDX022 for the Treatment of Hyperkalemia (NASDAQ:ARDX) - January 5 at 6:16 AM


Ardelyx (NASDAQ:ARDX) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff